The Prognostic Significance of Hsp70 in Patients with Colorectal Cancer Patients: A PRISMA-Compliant Meta-Analysis

Guangyu Gao, Songtao Liu, Zhen Yao, Yanyan Zhan, Wenyue Chen, and Yulong Liu

1Department of Nuclear Accident Medical Emergency, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
2Department of Ultrasound, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
3State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China
4Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou 215123, China

Correspondence should be addressed to Yulong Liu; yulongliu2002@suda.edu.cn

Received 1 February 2021; Revised 31 March 2021; Accepted 6 April 2021; Published 16 April 2021

Academic Editor: Ning Cao

Copyright © 2021 Guangyu Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Hsp70 (heat shock protein 70) plays a key role in carcinogenesis and cancer progression. However, the relationship between the Hsp70 expression level and the colorectal cancer patient survival is unknown. This study is aimed at investigating the relationship between Hsp70 and the prognosis of colorectal carcinoma patients.

Methods. PubMed, Web of Science, and Embase were used for systematic computer literature retrieval. Stata SE14.0 software was used for quantitative meta-analysis. Besides, data was extracted from selected articles. Relationships between Hsp70 expression level and prognosis were further studied. The hazard ratios (HRs) and 95% confidence intervals (95% CIs) were also computed.

Results. A total of 11 potentially eligible studies with 2269 patients were identified in 10 tumors from PubMed, Web of Science, and Embase. Hsp70 overexpression was associated with poor overall survival (OS) and disease-free survival (DFS) in colorectal carcinoma patients (HRs, 0.65 (95% CI: 0.52-0.78) and 0.77 (95% CI: 0.23-1.32), respectively).

Conclusions. Hsp70 overexpression can predict poor survival in colorectal cancer patients.

1. Introduction

Colorectal cancer (CRC) is a serious health problem worldwide. The response and overall survival of advanced colorectal cancer patients are very poor compared with the early stage. While colorectal cancer can be treated through surgery, tumor recurrence develops in about 25% to 40% of patients [1]. Surgical tumor resection is the major treatment method for local advanced colorectal cancer. However, there is no effective treatment for metastatic tumors, especially those that cannot be surgically removed and those with poor chemotherapy and radiotherapy effects [2].

Hsps are well-maintained molecules overexpressed in cells subjected to various stress stimuli (heat shock or disruption of homeostasis). Hsps act as molecular chaperones assisting protein folding in normal metabolic conditions and promoting protein repair and stabilization during molecular stress [3]. Hsps are essential in cellular defense against carcinogenesis [4]. Their tumorigenesis role includes oncogenic protein stabilization, programmed cell death, replicative senescence inhibition, tumor angiogenesis induction, invasion, and metastasis activation [5]. Interestingly, most Hsp70 expression studies are based on colorectal cancer cell lines and xenografts and not actual biopsy samples [6].

Studies have shown that Hsp70 expression is upregulated in various carcinoma tissues and could be a potential biomarker [7]. Besides, previous studies have reported that Hsp70 overexpression is associated with poor survival in some cancers, including breast carcinoma [8–10], esophageal adenocarcinoma [11], non-small-cell lung cancer [12],
Two authors (GY and ZY) extracted researches were included. Text word and MeSH strategy ware used for all data analyses. Two researchers independently extracted the studies. The inclusion criteria were as follows: (a) studies showing the relationship between the Hsp70 expression level and OS or DFS in colorectal carcinoma, (b) studies describing the relationship between clinicopathological parameters and Hsp70 expression levels in human carcinoma tissues, (c) studies grouping patients (two groups) based on Hsp70 expression level, and (d) if hazard ratios and 95% confidence intervals could be calculated. The exclusion criteria were as follows: (a) studies with insufficient information to compute hazard ratios and 95% confidence intervals or (b) letters, case reports, expert opinions, and reviews or (c) in vitro or animal studies. Besides, only English researches were included.

2.3. Data Extraction. Two authors (GY and ZY) extracted data from identified articles that complied with the standards, and a third researcher resolved different opinions. The first author, country, year of publication, tumor type, sample size, study design, cut-off value, follow-up time, methods used, and the outcome were recorded. Hazard ratios with 95% confidence intervals for overall survival or disease-free survival were also determined. Engauge Digitizer version 4.1 was used to calculate prognosis after drawing the Kaplan-Meier curves [24].

2.4. Statistical Methods. The prognostic value of the Hsp70 expression level in colorectal cancer patients was determined by estimating the hazard ratios between the upregulated and downregulated Hsp70 tissue groups for overall survival or disease-free survival. The 95% confidence intervals and the heterogeneity were also calculated and evaluated based on P value and $I^2$. Furthermore, $I^2 > 50\%$ indicated significant heterogeneity. The random-effects model was used to determine the total hazard ratios. A fixed-effects model was used when $I^2 \leq 50\%$ (moderate heterogeneity). The Stata 14.0 software was used for all data analyses.

2. Methods

2.1. Literature Retrieval. Studies published between July 9, 1989 and July 9, 2020 were downloaded from PubMed, Web of Science, and Embase. Text word and MeSH strategy were used for the retrieval. The following terms were used: heat shock protein 70 OR Hsp70 AND colorectal AND cancer OR carcinoma OR malignant OR neoplasm OR tumor. Besides, the reference lists of the retrieved studies were manually screened for additional literature retrieval.

2.2. Selection Criteria. Two researchers independently extracted the studies. The inclusion criteria were as follows: (a) studies showing the relationship between the Hsp70 expression level and OS or DFS in colorectal carcinoma, (b) studies describing the relationship between clinicopathological parameters and Hsp70 expression levels in human carcinoma tissues, (c) studies grouping patients (two groups) based on Hsp70 expression level, and (d) if hazard ratios and 95% confidence intervals could be calculated. The exclusion criteria were as follows: (a) studies with insufficient information to compute hazard ratios and 95% confidence intervals or (b) letters, case reports, expert opinions, and reviews or (c) in vitro or animal studies. Besides, only English researches were included.

2.3. Data Extraction. Two authors (GY and ZY) extracted data from identified articles that complied with the standards, and a third researcher resolved different opinions. The first author, country, year of publication, tumor type, sample size, study design, cut-off value, follow-up time, methods used, and the outcome were recorded. Hazard ratios with 95% confidence intervals for overall survival or disease-free survival were also determined. Engauge Digitizer version 4.1 was used to calculate prognosis after drawing the Kaplan-Meier curves [24].

2.4. Statistical Methods. The prognostic value of the Hsp70 expression level in colorectal cancer patients was determined by estimating the hazard ratios between the upregulated and downregulated Hsp70 tissue groups for overall survival or disease-free survival. The 95% confidence intervals and the heterogeneity were also calculated and evaluated based on P value and $I^2$. Furthermore, $I^2 > 50\%$ indicated significant heterogeneity. The random-effects model was used to determine the total hazard ratios. A fixed-effects model was used when $I^2 \leq 50\%$ (moderate heterogeneity). The Stata 14.0 software was used for all data analyses.

3. Results

3.1. Included Studies and Characteristics. The research procedure is shown in Figure 1. A total of 1085 articles were selected after screening Web of Science, Embase, and PubMed. A total of 890 studies were excluded after the title and abstract search. Moreover, 142 articles were excluded since they did not meet the inclusion criteria. Another 42 records had insufficient data for HR calculation. Finally, 11 articles with 2269 patients were used [21–23, 25–32]. The 11 articles had a sample size of 167 to 256 (average 206) (Table 1). Besides, the 11 articles were published between 2009 and 2020 from various countries, including Hungary (4), Korea (2), and Britain, Greece, and Jordan (1 each). Most articles used immunohistochemistry (IHC) to determine the Hsp70 expression level.

3.2. High Hsp70 Expression Is Associated with Poor OS. Systematic meta-analysis was used to assess the relationship between the Hsp70 expression level and OS in colorectal cancer patients. Meta-analysis of nine articles with 1917 colorectal cancer patients showed that Hsp70 expression was significantly associated with OS (HR 0.65; 95% CI: 0.52-0.78; Figure 2), indicating that Hsp70 overexpression is associated with poor survival. A fixed-effects model was used since no significant heterogeneity was found ($I^2 = 0\%$) in the identified studies.

3.3. High Hsp70 Expression Is Associated with Poor DFS. The relationship between Hsp70 expression and disease-free survival of 352 cancer patients was also investigated (Figure 3). A fixed-effects model was used since there was no significant heterogeneity ($I^2 = 0\%$). The upregulated Hsp70 was associated with poor disease-free survival (HR = 0.77, 95% CI: 0.23-1.32).

3.4. Publication Bias. Begg’s and Egger’s tests were used to evaluate the publication bias via funnel plot symmetry estimation. There was no significant asymmetry of the funnel plots. Therefore, this study has no significant publication bias [33] (Figures 4 and 5). A sensitivity analysis was also conducted to verify the credibility of hazard ratios for overall survival. There were no significant impacts on HRs after excluding any one study, suggesting result reliability (Figure 6).

4. Discussion

In recent years, potential prognostic biomarkers have been identified to improve the efficacy and survival rate. However, the prognosis of most cancers is relatively low. Therefore, high/positive tissue Hsp70 expression could be associated with the prognosis of colorectal carcinoma patients. Furthermore, previous studies have concluded that Hsp70 expression has biological and clinical significance. However, various cancers have different results. Hsp70 is significantly upregulated in gastric, breast, and prostate carcinoma compared with the normal tissues. In contrast, some articles have indicated that Hsp70 is significantly downregulated in cancer tissues compared with normal tissues in malignant
Records identified through database searching \( (n = 1085) \)

Additional records identified through other sources \( (n = 0) \)

Records after duplicates removed \( (n = 1085) \)

Records screened \( (n = 195) \)

Records excluded by screened title an abstract \( (n = 890) \)

Full-text articles assessed for eligibility \( (n = 53) \)

Records failed to meet our eligibility criteria after screening the full texts \( (n = 142) \)

Studies included in qualitative synthesis \( (n = 11) \)

HRs of recod can not be calculated. \( (n = 42) \)

Studies included in quantitative synthesis (meta-analysis) \( (n = 11) \)

**Figure 1:** The flow chart of the selection process in the meta-analysis.

**Table 1:** Main characteristics of the 11 studies in the meta-analysis.

| Study | Country  | Year  | Sample | Study design | Sizes | Cut-off value | Gender (female/male) | Follow-up time (month) | Tumor stage (I/II/III/IV) | Outcome | Method | NOS |
|-------|----------|-------|--------|--------------|-------|---------------|----------------------|------------------------|--------------------------|---------|--------|-----|
| Dundas, S. et al. | Britain | 2005 | CRC R | 231 | 25% | NA | 0-120 | NA | OS | IHC | 7 |
| Graf, L. et al. | Hungary | 2018 | CRC R | 232 | 20% | 112/120 | 0-60 | NA | OS | IHC | 7 |
| Jubran, R. et al. | Hungary | 2017 | CRC R | 227 | NR | 121/106 | 0-60 | 30/40/60/97 | OS | IHC | 8 |
| Kocsis, J. et al. | Hungary | 2009 | CRC R | 178 | NR | 89/88 | 33 (24-44) | 25/26/60/67 | OS | IHC | 9 |
| Kocsis, J. et al. | Hungary | 2010 | CRC R | 254 | NR | NA | 33.0 (23.5–43.5) | 80/60/110/4 | OS | IHC | 8 |
| Lazaris, A. et al. | Greece | 1997 | CRC R | 128 | 25% | NA | 44.76 (0-222.36) | NA | OS | IHC | 9 |
| Jogi, A. et al. | Sweden | 2009 | CRC R | 196 | 25% | NA | 0-60 | NA | OS | IHC | 8 |
| Shotar, A. et al. | Jordan | 2005 | CRC R | 215 | 20% | 112/103 | 6.88 (0.64-17.05) | 40/32/79/64 | OS | IHC | 8 |
| Sun, X. et al. | Sweden | 1997 | CRC R | 256 | 20% | 122/134 | 0-156 | NA | OS | IHC | 7 |
| S Kim, J. et al. | Korea | 2014 | CRC R | 167 | 25% | NA | 29 (0-120) | NA | DFS | IHC | 9 |
| Oh, H. et al. | Korea | 2017 | CRC R | 185 | NR | 90/95 | 51.1 (3.1-57.1) | NA | DFS | IHC | 9 |

Abbreviation: CRC: colorectal cancer; R: retrospective analysis; NR: not report; OS: overall survival; DFS: disease-free survival; IHC: immunohistochemistry; NA: not available; NOS: Newcastle-Ottawa Scale.
| Study ID          | ES (95%CI)       | Weight |
|------------------|------------------|--------|
| Dundas, S. et al.| 0.54 (0.27, 0.88)| 18.00  |
| Graf, L. et al.  | 0.88 (0.32, 1.45)| 5.22   |
| Jubran, R. et al.| 0.65 (0.25, 1.06)| 10.05  |
| Kocsis, J. et al.| 0.77 (0.12, 1.38)| 4.20   |
| Kocsis, J. et al.| 0.52 (0.19, 0.87)| 14.43  |
| Lazaris, A. et al.| 0.67 (0.41, 0.99)| 20.06  |
| Jogi, A. et al.  | 1.26 (0.56, 1.95)| 3.47   |
| Shotar, A. et al.| 0.79 (0.36, 1.39)| 6.29   |
| Sun, X. et al.   | 0.58 (0.31, 0.91)| 18.28  |
| Overall (I-squared = 0.0%, P = 0.727) | 0.65 (0.52, 0.78) | 100.00 |

**Figure 2:** The relationship between Hsp70 expression and overall survival (OS) in human colorectal cancer.

| Study ID          | ES (95%CI)       | Weight |
|------------------|------------------|--------|
| Kim, J. et al.   | 0.74 (0.11, 1.38)| 73.00  |
| Oh, H. et al.    | 0.85 (-0.20, 1.90)| 27.00  |
| Overall (I-squared = 0.0%, P = 0.866) | 0.77 (0.23, 1.32) | 100.00 |

**Figure 3:** Forest plot indicating the association between Hsp70 expression and DFS.

**Figure 4:** Begg and Egger tests of OS.
melanoma, colon cancer, and urothelial bladder cancer. The different results could be due to the various interactions between Hsp70 and other human gene products in different organs. Recent articles have verified that Hsp70 overexpression is associated with poor survival in breast cancer, colorectal cancer, melanoma, gastric cancer, hepatocellular carcinoma, non-small-cell lung cancer, ovarian cancer, and testicular cancer. Besides, Hsp70 overexpression is not associated with esophageal adenocarcinoma and esophageal squamous cell cancer, while it is associated with better survival in urinary bladder cancer and pancreatic cancer. Sun et al. reported no significant relationships between Hsp with sex or age of patients, tumor site, Duke’s stage, growth pattern, or differentiation [34]. Shotar also reported that there is no significant relationship between the HSP70 and p53 expressions [30]. Similarly, Kocsis et al. reported that mortalin blood analysis, mortalin, and sHSP70 have a high prognostic value at the TNM stage and can identify colorectal cancer patients at high risk of poor survival [29]. Oh et al. also reported that the dominant intensity score-based Hsp70 IHC interpretation can be an effective method for MSI-H-prognostic stratification (a high level of microsatellite instability) in colorectal cancer [22]. In this study, the prognostic value and clinicopathologic significance of Hsp70 in colorectal carcinoma patients were assessed. This study can help understand the tumor generation process and the treatment value of Hsp70 in colorectal cancer. The meta-analysis included 2269 tumor patients from 11 articles (Hungary (4), Korea (2), and Britain, Greece, and Jordan (1 each)). A fixed-effects model was used for heterogeneity examination. The combined HRs indicated that Hsp70 overexpression was associated with the poor prognosis of colorectal carcinoma.

**Figure 5:** Begg and Egger tests of DFS.

**Figure 6:** Sensitivity analysis evaluating the impact of each research.
patients. Hsp70 overexpression was also related to poor DFS. However, a large study should be conducted to verify these results.

Notably, this study has several limitations. First, some survival statistics from digital computer technology should be carefully considered. Besides, non-English articles were excluded. Second, only 11 articles with 2269 patients were included. There were no enough articles for subgroup analyses on disease-free survival. Third, different studies had different definitions of Hsp70 expression. Therefore, more researches are needed for more inclusive conclusions.

5. Conclusion

Hsp70 overexpression is significantly associated with poor overall survival and disease-free survival in colorectal carcinoma patients. Several such studies can provide mechanistic, pathophysiological, and epidemiological evidence complementing the findings of the current clinical trials on Hsp70 inhibitors.

Abbreviations

Hsp70: Heat shock protein 70  
CI: Confidence intervention  
Embase: Excerpta Medica database  
HR: Hazard ratio  
OS: Overall survival  
DFS: Disease-free survival  
CRC: Colorectal cancer.

Data Availability

All data included in this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

All authors confirmed result accuracy. Guangyu Gao, Zhen Yao, and Nanping Lin conceived and designed the study; acquired, analyzed, and interpreted the data; and drafted the article. Yingchao Wang revised the article while Xiaolong Liu and Jingfeng Liu critically revised it. The report was finally approved. Songtiao Liu and Guangyu Gao equally contributed to this work.

Acknowledgments

The authors thank Dr. Yulong Liu for the support.

References

[1] S. R. Steele, G. J. Chang, S. Hendren et al., “Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer,” Diseases of the Colon and Rectum, vol. 58, no. 8, pp. 713–725, 2015.

[2] J. D. Vogel, C. Eskiçioglu, M. R. Weiser, D. L. Feingold, and S. R. Steele, “The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of colon cancer,” Diseases of the Colon and Rectum, vol. 60, no. 10, pp. 999–1017, 2017.

[3] H. Wang, M. S. Tan, R. C. Lu, J. T. Yu, and L. Tan, “Heat Shock Proteins at the Crossroads between Cancer and Alzheimer’s Disease,” BioMed Research International, vol. 2014, Article ID 239164, 9 pages, 2014.

[4] M. C. Diehl, M. O. Idowu, K. Kimmelshue, T. P. York, L. W. Elmore, and S. E. Holt, “Elevated expression of nuclear Hsp90 in invasive breast tumors,” Cancer Biology & Therapy, vol. 8, no. 20, pp. 1952–1961, 2009.

[5] R. Moradi-Marjaneh, M. Paseban, and M. Moradi Marjaneh, “Hsp70 inhibitors: implications for the treatment of colorectal cancer,” IUBMB Life, vol. 71, no. 12, pp. 1834–1845, 2019.

[6] E. Turrini, E. Catanzaro, M. G. Muraro et al., “Hemidesmus indicus induces immunogenic death in human colorectal cancer cells,” Oncotarget, vol. 9, no. 36, pp. 24443–24456, 2018.

[7] D. T. Dimas, C. D. Perlepe, T. N. Sergentanis et al., “The prognostic significance of Hsp70/Hsp90 expression in breast cancer: a systematic review and meta-analysis,” Anticancer Research, vol. 38, no. 3, pp. 1551–1562, 2018.

[8] A. Kologeraki, E. Giannikaki, M. Tzardi et al., “Correlation of heat shock protein (HSP70) expression with cell proliferation (MBI1), estrogen receptors (ER) and clinicopathological variables in invasive ductal breast carcinomas,” Journal of Experimental & Clinical Cancer Research, vol. 26, no. 3, pp. 367-368, 2007.

[9] A. Lazaris, E. B. Chatzigianni, D. Panoussopoulos, G. N. Tzimas, P. S. Davaris, and B. Golematis, “Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified,” Breast Cancer Research and Treatment, vol. 43, no. 1, pp. 43–51, 1997.

[10] D. R. Ciocca, G. M. Clark, A. K. Tandon, S. A. Fuqua, W. J. Welch, and W. L. McGuire, “Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications,” Journal of the National Cancer Institute, vol. 85, no. 7, pp. 570–574, 1993.

[11] H. K. Söderström, J. T. Kauppi, N. Oksala et al., “Overexpression of HSP27 and HSP70 is associated with decreased survival among patients with esophageal adenocarcinoma,” World Journal of Clinical Cases, vol. 7, no. 3, pp. 260–269, 2019.

[12] J. Sun, S. L. Che, J. J. Piao, M. Xu, L. Y. Chen, and Z. H. Lin, “Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer,” Tumour Biology, vol. 39, no. 3, p. 1010428317695918, 2017.

[13] S. Kumar, S. Gurshaney, Y. Adagunodo et al., “Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer,” Frontiers in Bioscience (Landmark edition), vol. 23, pp. 1987–2000, 2018.

[14] A. Glaesgen, S. Jonmarker, A. Lindberg et al., “Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer,” APMIS, vol. 116, no. 10, pp. 888–905, 2008.

[15] E. Zhai, W. Liang, Y. Lin et al., “HSP70/HSP90-organizing protein contributes to gastric cancer progression in an autocrine fashion and predicts poor survival in gastric cancer,” Cellular Physiology and Biochemistry, vol. 47, no. 2, pp. 879–892, 2018.

[16] A. Kimura, K. Ogata, B. Altani et al., “Nuclear heat shock protein 110 expression is associated with poor prognosis and
hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis,” World Journal of Gastroenterology, vol. 23, no. 42, pp. 7541–7550, 2017.

[17] K. Klikova, I. Pilchova, A. Stefanikova, J. Hatok, D. Dobrota, and P. Racay, “The role of heat shock proteins in leukemia,” Klinická Onkologie, vol. 29, no. 1, pp. 29–38, 2016.

[18] C. Wang, Y. Zhang, K. Guo et al., “Heat shock proteins in hepatocellular carcinoma: molecular mechanism and therapeutic potential,” International Journal of Oncology, vol. 138, no. 8, pp. 1824–1834, 2016.

[19] L. Jiang, D. L. Kwong, Y. Li et al., “HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma,” Carcinogenesis, vol. 36, no. 10, pp. 1111–1120, 2015.

[20] X. Cui, Z. Li, J. Piao et al., “Mortalin expression in pancreatic cancer and its clinical and prognostic significance,” Human Pathology, vol. 64, pp. 171–178, 2017.

[21] L. Gráf, L. Barabás, B. Madaras et al., “High serum Hsp70 level predicts poor survival in colorectal cancer: results obtained in an independent validation cohort,” Cancer Biomarkers, vol. 23, no. 4, pp. 539–547, 2018.

[22] H. J. Oh, J. H. Kim, T. H. Lee et al., “Dominant high expression of wild-type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole-section immunohistochemical analysis,” APMIS, vol. 125, no. 12, pp. 1076–1083, 2017.

[23] J. H. Kim, K. J. Kim, Y. Y. Rhee et al., “Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer,” Modern Pathology, vol. 27, no. 3, pp. 443–453, 2014.

[24] M. K. Parmar, V. Torri, and L. Stewart, “Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints,” Statistics in Medicine, vol. 17, no. 24, pp. 2815–2834, 1998.

[25] R. Jubran, J. Kocsis, N. Garam et al., “Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: risk indicators in colorectal cancer,” International Journal of Cancer, vol. 141, no. 11, pp. 2329–2335, 2017.

[26] P. Rozenberg, J. Kocsis, M. Saar, Z. Prohaszka, G. Fust, and Z. Fishelson, “Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer,” International Journal of Cancer, vol. 133, no. 2, pp. 514–518, 2013.

[27] K. Bauer, U. Nitsche, J. Slotta-Huspenina et al., “High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer,” Cellular Oncology (Dordrecht), vol. 35, no. 3, pp. 197–205, 2012.

[28] J. Kocsis, T. Mészáros, B. Madaras et al., “High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer,” Cell Stress & Chaperones, vol. 16, no. 1, pp. 49–55, 2011.

[29] J. Kocsis, B. Madaras, E. K. Toth, G. Fust, and Z. Prohaszka, “Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis,” Cell Stress & Chaperones, vol. 15, no. 2, pp. 143–151, 2010.

[30] A. M. Shotar, “p53 and heat shock protein 70 expressions in colorectal adenocarcinoma,” Saudi Medical Journal, vol. 26, no. 10, pp. 1602–1606, 2005.

[31] S. R. Dundas, L. C. Lawrie, P. H. Rooney, and G. I. Murray, “Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival,” The Journal of Pathology, vol. 205, no. 1, pp. 74–81, 2005.